Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study
Kim B Handoko1, Jeannette E F Zwart-van Rijkom, Walter A J J Hermens
1Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
Pharmacoepidemiology and Drug Safety
|October 13, 2006
Summary
Changes in antiepileptic drug (AED) therapy were not significantly linked to epilepsy hospitalizations. However, starting three or more new non-AED medications nearly quintupled the risk of epilepsy-related hospital admission.
Area of Science:
- Clinical Pharmacology
- Epileptology
- Pharmacoepidemiology
Background:
- Medication changes are common in epilepsy management.
- Understanding the impact of these changes on hospitalization risk is crucial for patient safety.
- Previous research has not fully elucidated the specific risks associated with various medication modification patterns.
Purpose of the Study:
- To investigate the association between modifications in antiepileptic drug (AED) therapy and epilepsy-related hospitalizations.
- To evaluate the impact of changes in AED pattern and dosage, interacting co-medications, and non-interacting co-medications on hospitalization risk.
Main Methods:
- A case-crossover study design was employed using data from the PHARMO Record Linkage System (1998-2002).
- Patients with a first epilepsy-related hospital admission and continuous AED use were included.
- Medication changes within a 28-day window preceding hospitalization were compared to earlier periods using conditional logistic regression.
Main Results:
- Discontinuation of AEDs showed a trend towards increased hospitalization risk (OR: 2.57).
- Introduction of three or more non-AEDs was significantly associated with epilepsy-related hospitalization (OR: 4.80).
- Addition of antimicrobial agents was also significantly associated with increased hospitalization risk (OR: 1.99).
Conclusions:
- While changes in AED therapy itself were not significantly linked to epilepsy hospitalizations, initiating multiple new non-AEDs substantially elevates this risk.
- Few drug interactions directly impacting AED therapy were identified.
- This highlights the importance of monitoring non-antiepileptic drug initiation in patients with epilepsy.
Related Concept Videos
01:16Crossover Experiments
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...